维普期刊资源整合服务平台（V6.5）

34篇 您的检索式：作者名="Kates RE"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Efficacy of Radiofrequency Ablation Combined With Endoscopic Resection for Barrett’s Esophagus With Early Neoplasia显示文摘	Roos E. Pouw Katja Wirths Pierre Eisendrath Carine M. Sondermeijer Fiebo J. Ten Kate Paul Fockens Jacques Devière Horst Neuhaus Jacques J. Bergman	2010	Clinical Gastroenterology and Hepatology2010，，：	2
2	Enhanced benefit fi'om adjuvant chemotherapy in breast cancer patients classified high-risk accoding to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor typel ( N = 3424) 显示文摘	Harbeck N Kates RE Look MP Meijer-van Gelder ME Klijn JGM Kruger A	2002	Cancer Res2002，2，16：	1
3	Invasive factors uPA/PAI-1 and HER-2 status provide independent and complementary information in patient outcome in node-negative breast cancer显示文摘	Zemzoum I Kates RE Ross JS	2003	J Clin Oncol2003，21，6：	1
4	Health economic impactof risk group selection according to ASC 0 -recommended biomarkersuPA/PAI-1 in node-negative primary breast cancer 显示文摘	Jacobs VR Kates RE Kantelhardt E	2013	Breast Canc-er Res Treat2013，138，3：	1
5	Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 determination in primary breast cancer tissue for individualized therapy concepts显示文摘	Harbeck N Schmitt M Kates RE	2002	Clin Breast Cancer2002，3，3：	1
6	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer 显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，5：	1
7	Interaction between warfarin and propafenone in healthy volunteer subjects 显示文摘	Kates RE Yee YG Kirsten EB	1987	Clin Pharmacol Ther1987，42，3：	1
8	Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts显示文摘	Harbeck N Schmitt M Kates RE	2002	Clin Breast Cancer2002，3，3：	1
9	Urokinase-type plasminogen activator(uPA) and its inhibitor PAI-I:novel tumor-derived factors with a high prognostic and predictive impact in breast cancer显示文摘	Harbeck N Kates RE Gauger K	2004	Thromb Haemost2004，1，3：	1
10	Urokinase- type plasminogen activator and its inhibitor type 1 pre- dict disease outcome and therapy response in primary breast cancer显示文摘	Harbeck N Kates RE Schmitt M	2004	Clinical breast cancer2004，5，5：	1
11	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer 显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，：	1
12	Urokinase - type plasmino- gen activator and its inhibitor type 1 predict disease outcome and therapy response inprimary breast cancer显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，5：	1
13	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，：	1
14	Urokinasetype plasminogen activator (uPA) and its inhibitor PAI-Ⅰ:novel tumor-derived factors with a high prognostic and predictive impact in breast cancer显示文摘	Harbeck N Kates RE Gauger K	2004	Thrombosis and Haemostasis2004，91，：	1
15	Urokinase - type plasminogen activator and its inhibitor type 1 predict disease outcome andtherapy response in primary breast cancer显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，5：	1
16	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer显示文摘	Harbeck N Kates RE Schmitt M	2004	Clin Breast Cancer2004，5，5：	1
17	Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1:novel tumor-derived factors with a high prognostic and predictive impact in breast cancer显示文摘	Harbeck N Kates RE Gauger K	2004	Thromb Haemost2004，1，13：	1
18	Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-Ⅰ:novel tumor-derived factors with a high prognostic and predictive impact in breast cancer显示文摘	Kates RE Gauger K	2004	Thromb Haemost2004，91，3：	1
19	Clinical utility of inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts显示文摘	Schmitt M Kates RE	2002	Clin Breast Cancer2002，3，3：	1
20	Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination显示文摘	Harbeck N Kates RE Schmitt M	2002	J Clin Oncol2002，20，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示